Alkem Medtech Executes First Supplementary Agreement in Occlutech Acquisition
Alkem Laboratories Limited's subsidiary, M/s. Alkem Medtech Private Limited, has formalized a significant step toward acquiring a stake in the Swiss company, Occlutech Holding AG.Alkem Medtech was initially informed of plans to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech, which is a company incorporated in Switzerland. This intention follows the execution of an initial Share Purchase Agreement with the selling shareholders of Occlutech.
In continuation of these proceedings, it was reported that on June 26, 2026, Alkem Medtech executed the First Supplementary Agreement to Share Purchase Agreement. This supplementary agreement was executed with the selling shareholders of Occlutech. The original Share Purchase Agreement for reference is dated March 6, 2026.
ALKEM Stock Price Movement
Shares of Alkem Laboratories Limited are edging higher to ₹5517.50 as of 9:50 AM, pushing the pharmaceutical stocks up by 1.71%. The equity traded a total volume of 28,553 shares during the live market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.